These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. Sharma A; Sharma S; Khuller GK J Antimicrob Chemother; 2004 Oct; 54(4):761-6. PubMed ID: 15329364 [TBL] [Abstract][Full Text] [Related]
6. Chemotherapy of Mycobacterium tuberculosis infections in mice with a combination of isoniazid and rifampicin entrapped in Poly (DL-lactide-co-glycolide) microparticles. Dutt M; Khuller GK J Antimicrob Chemother; 2001 Jun; 47(6):829-35. PubMed ID: 11389115 [TBL] [Abstract][Full Text] [Related]
7. Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis. Pandey R; Zahoor A; Sharma S; Khuller GK Tuberculosis (Edinb); 2003; 83(6):373-8. PubMed ID: 14623168 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic efficacy of Poly(DL-lactide-Co-Glycolide)-encapsulated antitubercular drugs against Mycobacterium tuberculosis infection induced in mice. Dutt M; Khuller GK Antimicrob Agents Chemother; 2001 Jan; 45(1):363-6. PubMed ID: 11121000 [TBL] [Abstract][Full Text] [Related]
10. Nanoparticle encapsulated lipopeptide conjugate of antitubercular drug isoniazid: in vitro intracellular activity and in vivo efficacy in a Guinea pig model of tuberculosis. Horváti K; Bacsa B; Kiss E; Gyulai G; Fodor K; Balka G; Rusvai M; Szabó E; Hudecz F; Bősze S Bioconjug Chem; 2014 Dec; 25(12):2260-8. PubMed ID: 25394206 [TBL] [Abstract][Full Text] [Related]
11. Oral poly(lactide-co-glycolide) nanoparticle based antituberculosis drug delivery: toxicological and chemotherapeutic implications. Pandey R; Sharma S; Khuller GK Indian J Exp Biol; 2006 Jun; 44(6):459-67. PubMed ID: 16784116 [TBL] [Abstract][Full Text] [Related]
12. Oral nanoparticle-based antituberculosis drug delivery to the brain in an experimental model. Pandey R; Khuller GK J Antimicrob Chemother; 2006 Jun; 57(6):1146-52. PubMed ID: 16597631 [TBL] [Abstract][Full Text] [Related]
13. Sustained release of isoniazid from a single injectable dose of poly (DL-lactide-co-glycolide) microparticles as a therapeutic approach towards tuberculosis. Dutt M; Khuller GK Int J Antimicrob Agents; 2001 Feb; 17(2):115-22. PubMed ID: 11165115 [TBL] [Abstract][Full Text] [Related]
14. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Pandey R; Khuller GK Tuberculosis (Edinb); 2005 Jul; 85(4):227-34. PubMed ID: 15922668 [TBL] [Abstract][Full Text] [Related]
15. Nanoparticle-based oral drug delivery system for an injectable antibiotic - streptomycin. Evaluation in a murine tuberculosis model. Pandey R; Khuller GK Chemotherapy; 2007; 53(6):437-41. PubMed ID: 17952004 [TBL] [Abstract][Full Text] [Related]
17. Chemotherapeutic potential of alginate-chitosan microspheres as anti-tubercular drug carriers. Pandey R; Khuller GK J Antimicrob Chemother; 2004 Apr; 53(4):635-40. PubMed ID: 14998985 [TBL] [Abstract][Full Text] [Related]
18. Oral therapy using nanoparticle-encapsulated antituberculosis drugs in guinea pigs infected with Mycobacterium tuberculosis. Johnson CM; Pandey R; Sharma S; Khuller GK; Basaraba RJ; Orme IM; Lenaerts AJ Antimicrob Agents Chemother; 2005 Oct; 49(10):4335-8. PubMed ID: 16189115 [TBL] [Abstract][Full Text] [Related]
19. Chemotherapy of tuberculosis in mice using single implants of isoniazid and pyrazinamide. Gangadharam PR; Geeta N; Hsu YY; Wise DL Int J Tuberc Lung Dis; 1999 Jun; 3(6):515-20. PubMed ID: 10383065 [TBL] [Abstract][Full Text] [Related]
20. Role of poly [DL-lactide-co-glycolide] in development of a sustained oral delivery system for antitubercular drug(s). Ain Q; Sharma S; Garg SK; Khuller GK Int J Pharm; 2002 Jun; 239(1-2):37-46. PubMed ID: 12052689 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]